NFKB1 and triple-negative breast carcinoma: Another group [35] found that, in triple-negative breast cancer-bearing mice, CUR ameliorated the muscle malignant metabolic profile, mitochondrial dysfunction, ubiquitination, and inflammation by modulating the NF-κB/UPS axis.